ProCE Banner Activity

DESTINY-Lung01: Phase II Trial of Trastuzumab Deruxtecan in HER2-Mutated Metastatic NSCLC

Slideset Download
Conference Coverage
In this single-arm study in patients with previously treated HER2-mutated NSCLC, trastuzumab deruxtecan demonstrated robust antitumor activity with a safety profile consistent with previous reports.

Released: September 27, 2021

Expiration: September 26, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Daiichi Sankyo, Inc.

Exelixis, Inc.

Ipsen Biopharmaceuticals Inc